Transfer of novel academic research in vaccines into marketable products – a new business model
•Transferir como PPT, PDF•
1 gostou•649 visualizações
Transfer of novel academic research in vaccines into marketable products – a new business model By - Dr. Albrecht Läufer, CEO
![Corvay at BioAsia2009 Corvay´s Core Competences ,[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (11)
Destaque
Destaque (12)
Semelhante a Transfer of novel academic research in vaccines into marketable products – a new business model
Semelhante a Transfer of novel academic research in vaccines into marketable products – a new business model (20)
Mais de BioAsia: The Global Bio Business Forum
Mais de BioAsia: The Global Bio Business Forum (12)
Último
Último (20)
Transfer of novel academic research in vaccines into marketable products – a new business model
- 1. Corvay at BioAsia2009 „ Transfer of novel academic research in vaccines into marketable products – a new business model “ Dr. Albrecht Läufer, CEO
- 4. Vaccines - Global Needs, Global Markets Highly unmet medical needs: The BIG Three: HIV, Tuberculosis, Malaria. Diarrhea causing diseases. Hepatitis C. Cytomegalovirus. Dengue. Influenza. Cancer. Other diseases related to infections or immune system disorder. Corvay at BioAsia2009
- 5. Vaccines - Global Needs, Global Markets 21 bn USD global vaccine sales in 2008 (18.5 bn USD in 2007). Prevnar® 3bn USD; Gardasil 2.8 bn USD. Several others >1 bn. “ Classical” mainly pediatric market 6 – 7 bn USD, stable. New vaccines providing the growth. India: 1800 crores = approx 360 mill USD. Russia, Brazil, China, all South East Asia to become big markets. Corvay at BioAsia2009
- 6. Vaccines - Global Needs, Global Markets Another urgent need : In order to grow further , industry needs new, successful candidates. Corvay at BioAsia2009
- 12. Corvay at BioAsia2009 Partners in the Tb vaccine project
- 15. Corvay at BioAsia2009 Thank you very much Corvay GmbH Sofienstr. 6 D - 30159 Hannover phone: +49 511 44 98 95 31 fax: +49 511 44 98 95 99 [email_address] www.corvay.de